Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease.

Literature DB >> 7919307

Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease.

Abstract

Entities: Disease

Mesh：

Substances：
BCG Vaccine

Year: 1994 PMID： 7919307 DOI： 10.1016/0962-8479(94)90003-5

Source DB: PubMed Journal: Tuber Lung Dis ISSN： 0962-8479

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

1. Stopping routine vaccination for tuberculosis in schools.

Authors: Paul Fine
Journal: BMJ Date: 2005-09-24

2. Tuberculosis 2004: challenges and opportunities.

Authors: Jeffrey Glassroth
Journal: Trans Am Clin Climatol Assoc Date: 2005

Review 3. The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?

Authors: F Abebe; G Bjune
Journal: Clin Exp Immunol Date: 2006-09 Impact factor: 4.330

4. Performance of QuantiFERON®-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs.

Authors: Francesca Gabriele; Maria Trachana; Maria Simitsopoulou; Polixeni Pratsidou-Gertsi; Elias Iosifidis; Zoi Dorothea Pana; Emmanuel Roilides
Journal: World J Pediatr Date: 2017-06-22 Impact factor: 2.764

5. BCG Moreau Polish Substrain Infections in Patients With Inborn Errors of Immunity: 40 Years of Experience in the Department of Immunology, Children's Memorial Health Institute, Warsaw.

Authors: Ewa Bernatowska; Małgorzata Pac; Edyta Heropolitańska-Pliszka; Barbara Pietrucha; Nel Dąbrowska-Leonik; Małgorzata Skomska-Pawliszak; Katarzyna Bernat-Sitarz; Katarzyna Krzysztopa-Grzybowska; Beata Wolska-Kuśnierz; Nadia Bohynikova; Ewa Augustynowicz; Ewa Augustynowicz-Kopeć; Maria Korzeniewska-Koseła; Anna Wieteska-Klimczak; Janusz Książyk; Teresa Jackowska; Mirjam van den Burg; Jean-Laurent Casanova; Capucine Picard; Bożena Mikołuć
Journal: Front Pediatr Date: 2022-05-19 Impact factor: 3.569

10. The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model.

Authors: Michael Clark; D William Cameron
Journal: BMC Pediatr Date: 2006-03-03 Impact factor: 2.125

Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease.

1. Stopping routine vaccination for tuberculosis in schools.

2. Tuberculosis 2004: challenges and opportunities.

Review 3. The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?

4. Performance of QuantiFERON®-TB Gold In-Tube assay in children receiving disease modifying anti-rheumatic drugs.

5. BCG Moreau Polish Substrain Infections in Patients With Inborn Errors of Immunity: 40 Years of Experience in the Department of Immunology, Children's Memorial Health Institute, Warsaw.

Review 6. Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly.

7. Does the BCG vaccine have different effects on strains of tuberculosis?

8. Decrease in the incidence of culture-positive meningitis and cerebral tuberculomas in France from 1990 to 2007.

9. BCG vaccination in England since 2005: a survey of policy and practice.

10. The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model.